NCT07690371Phase 3Recruiting

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Study sponsor: Nektar Therapeutics · NKTR

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-05Estimated
Enrollment · participants510Estimated
Source updated2026-10-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.